Blood Based Biomarkers - Market Insights, Competitive Landscape, and Market Forecast - 2034

Blood Based Biomarkers Market Summary

Overview:

• The Blood Based Biomarkers market is estimated at USD 8.50 billion in 2025 and is projected to reach USD 18.50 billion by 2034. Growth is anchored in the rising burden of cancer, cardiovascular, and neurological disease, the shift toward non-invasive testing, and a wave of regulatory clearances led by the first blood tests for Alzheimer's disease.
• The global Blood Based Biomarkers market is growing at a CAGR of 9.0% during the forecast period from 2026 to 2034.
• By type, the genetic biomarkers segment dominated the Blood Based Biomarkers market with a 41% share in 2025.
• By application, the oncology segment dominated the Blood Based Biomarkers market with a 39% share in 2025.
• By technology, the immunoassays segment dominated the Blood Based Biomarkers market with a 36% share in 2025.
• By end user, the hospital and diagnostic laboratories segment dominated the Blood Based Biomarkers market with a 48% share in 2025.
• North America dominated the global Blood Based Biomarkers market revenue with a 44% share in 2025, representing the highest regional market share globally.

Blood based biomarkers are measurable biological indicators in the blood, including proteins, nucleic acids, cells, and metabolites, that provide information about a person's health, disease presence and progression, and response to treatment. Detected through minimally invasive blood draws, these biomarkers include genetic markers such as cell-free DNA, circulating tumor DNA, and microRNA, protein markers such as troponin, phosphorylated tau, and prostate-specific antigen, circulating tumor and other cells, and metabolites such as glucose and glycated hemoglobin. They are increasingly central to the early detection, diagnosis, monitoring, and management of cancer, cardiovascular disease, neurological disorders, metabolic conditions, and infectious diseases, and they support companion diagnostics, recurrence monitoring, and clinical-trial enrichment. The market spans biomarker types, detection technologies including immunoassays, polymerase chain reaction, next-generation sequencing, and mass spectrometry, and applications across hospitals, diagnostic and reference laboratories, and research settings. Propelled by the rising burden of chronic and age-related disease, the maturation of liquid biopsy, a transformative wave of blood tests for Alzheimer's disease, and the broad shift from invasive tissue biopsy toward fast, safe, repeatable blood testing, blood based biomarkers have become foundational infrastructure for precision and preventive medicine.

Blood Based Biomarkers Market Key Growth Drivers

• The rising global cancer burden is driving demand for blood-based oncology biomarkers, with the International Agency for Research on Cancer projecting cancer cases to rise from 20 million in 2022 to 35 million by 2050.
• The growing prevalence of neurological disorders such as Alzheimer's and Parkinson's disease, alongside aging populations, is driving demand for non-invasive blood-based diagnostics.
• A transformative wave of regulatory clearances for blood tests, including the first FDA-cleared blood test to aid Alzheimer's diagnosis in 2025, is accelerating clinical adoption.
• The maturation of liquid biopsy is enabling sensitive detection of circulating tumor DNA for cancer detection, treatment selection, and recurrence monitoring.
• The broad shift from invasive tissue biopsy toward faster, safer, and repeatable blood testing is expanding adoption across screening, diagnosis, and monitoring.
• Advances in artificial intelligence, proteomics, and multi-biomarker panels are improving accuracy and enabling predictive, risk-based precision diagnostics.
• The convergence of disease burden, non-invasive testing, regulatory progress, and technological advances is expected to sustain strong growth in the market through 2034.

Key Companies in Blood Based Biomarkers Market

The competitive landscape is led by the following active developers and providers:

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• Bio-Rad Laboratories, Inc.
• Quanterix Corporation
• Fujirebio Holdings, Inc.
• Guardant Health, Inc.

Factors Contributing to the Growth of the Blood Based Biomarkers Market

Market Drivers

Rising Global Cancer Burden and Liquid Biopsy Adoption

The most powerful driver of the blood based biomarkers market is the rising global cancer burden, coupled with the rapid adoption of liquid biopsy. The International Agency for Research on Cancer recorded 20 million new cancer cases in 2022 and projects 35 million by 2050, and oncology is the largest application for blood-based biomarkers. Liquid biopsy enables sensitive detection of circulating tumor DNA, often at low mutant allele frequencies, supporting early detection, treatment selection, and recurrence monitoring without invasive tissue sampling. Clinical studies have shown that a substantial share of advanced cancer patients carry actionable circulating tumor DNA mutations detectable only by blood-based testing, including resistance mutations that guide therapy. Genetic biomarkers such as circulating tumor DNA and cell-free DNA anchor the largest segment of the market. As cancer incidence climbs and liquid biopsy matures, demand for blood-based oncology biomarkers expands, anchoring market growth through the forecast period.

Growing Burden of Neurological Disease and the Alzheimer's Blood Test Revolution

The growing burden of neurological disease, led by Alzheimer's and Parkinson's, is the fastest-growing driver of the market. As populations age, the prevalence of dementia and neurodegenerative disorders rises, and blood-based biomarkers offer a simpler, faster, and less invasive alternative to costly amyloid positron-emission-tomography imaging and cerebrospinal-fluid testing. A transformative wave of blood tests for Alzheimer's has emerged, anchored by phosphorylated tau biomarkers such as pTau217 and pTau181, which consistently outperform earlier generations for detecting amyloid and tau pathology. The first FDA-cleared blood test to aid Alzheimer's diagnosis reached the United States market in 2025, professional-society guidelines now endorse high-performing blood tests for triage and, in appropriate patients, substitution for imaging or spinal-fluid testing, and the World Health Organization has issued preferred product characteristics for these diagnostics. This convergence of disease burden, clinical validation, and guideline support is rapidly expanding neurological blood-based biomarker demand across the forecast period.

Market Restraints

Despite strong momentum, the blood based biomarkers market faces material constraints. Analytical and clinical validation requirements are demanding, as blood-based tests must demonstrate high sensitivity and specificity across diverse populations and disease stages, and many biomarkers show lower sensitivity for early-stage disease, raising the risk of false negatives that provide false reassurance and false positives that trigger costly, anxiety-inducing confirmatory workups. Reimbursement remains uneven and immature across geographies and applications, and many advanced tests are offered as self-pay or laboratory-developed tests without broad payer or public coverage, constraining access and return on investment. Regulatory pathways are still evolving, particularly for novel and multi-analyte tests, lengthening development timelines and adding uncertainty, and the absence of approval for many tests limits guideline inclusion. Standardization and harmonization gaps across platforms, assays, and reference ranges complicate comparability and clinical interpretation, and the need for confirmatory imaging or tissue testing in some settings limits standalone use. High costs of advanced platforms and the need for specialized infrastructure and expertise constrain adoption, particularly in lower-resource settings, and data-privacy, governance, and equity considerations add complexity. Clinician and patient awareness remains uneven, and uncertainty about real-world impact on outcomes pending long-term evidence tempers uptake. Together, these validation, reimbursement, regulatory, standardization, and infrastructure barriers moderate the pace of growth, even as the underlying drivers of disease burden and non-invasive testing remain firmly intact.

Blood Based Biomarkers Market Segment Analysis

The Blood Based Biomarkers Market by Type (Genetic Biomarkers, Protein Biomarkers, Cellular Biomarkers, Metabolite Biomarkers), Application (Oncology, Cardiovascular Diseases, Neurological Diseases, Metabolic and Other Diseases), Technology (Immunoassays, Polymerase Chain Reaction, Next-Generation Sequencing, Mass Spectrometry, Others), End User (Hospital and Diagnostic Laboratories, Reference Laboratories, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies), and Geography (North America, Europe, Asia-Pacific, Rest of World).

By Type

Dominant Subsegment: Genetic Biomarkers. The genetic biomarkers category is expected to dominate the market.

Dominant: Genetic Biomarkers ~ 41%

The genetic biomarkers segment accounted for 41% of the Blood Based Biomarkers market in 2025. Genetic biomarkers are the leading type because circulating tumor DNA, cell-free DNA, microRNA, and other nucleic-acid markers anchor the high-value, fast-growing field of liquid biopsy in oncology, the largest application for blood-based biomarkers. These markers detect the presence of tumors, guide treatment selection, identify resistance mutations, and monitor minimal residual disease and recurrence, capturing substantial clinical and commercial value. The rising incidence of cancer, advances in sequencing and digital polymerase chain reaction, and growing demand for personalized medicine reinforce the segment's dominance, as genetic profiles increasingly direct targeted therapy. Protein biomarkers form a very large and established category, spanning cardiac troponin, prostate-specific antigen, and the phosphorylated tau markers driving the Alzheimer's blood-test wave, while cellular biomarkers, including circulating tumor cells, are the fastest-growing type as genomics and proteomics research and precision medicine expand, and metabolite biomarkers support metabolic disease. Nonetheless, the value, growth, and oncology centrality of genetic biomarkers secure their leadership across the forecast period.

By Application

Dominant Subsegment: Oncology. The oncology category is expected to dominate the market.

Dominant: Oncology ~ 39%

The oncology segment accounted for 39% of the Blood Based Biomarkers market in 2025. Oncology is the leading application because blood-based biomarkers are central to cancer detection, treatment selection, recurrence monitoring, and companion diagnostics, and because the rising global cancer burden continuously expands testing volumes. Liquid biopsy and circulating tumor DNA testing enable non-invasive detection of actionable mutations, minimal residual disease monitoring, and recurrence surveillance, and established tests detect circulating tumor DNA to guide therapy without tissue biopsy. The breadth of cancer types, the large and growing patient population, and strong research and development investment anchor the segment's dominance. Cardiovascular disease is a large application, anchored by high-volume cardiac biomarkers such as troponin for heart-attack detection and risk stratification, while neurological diseases are the fastest-growing application, propelled by the Alzheimer's blood-test wave and demand for non-invasive neurodegenerative diagnostics, and metabolic and other diseases contribute through markers such as glucose and glycated hemoglobin. Nonetheless, the scale, value, and research momentum of oncology secure its leadership across the forecast period.

By End User

Dominant Subsegment: Hospital and Diagnostic Laboratories. The hospital and diagnostic laboratories category is expected to dominate the market.

Dominant: Hospital and Diagnostic Laboratories ~ 48%

The hospital and diagnostic laboratories segment accounted for 48% of the Blood Based Biomarkers market in 2025. Hospital and diagnostic laboratories are the largest end user because they perform the overwhelming majority of blood-based biomarker tests, from routine cardiac and oncology markers to the new generation of neurological assays, and have the platforms, throughput, and clinical integration to deliver them at scale. These laboratories order, run, and interpret tests, integrate results into patient care, and coordinate follow-up, making them central to clinical adoption, and the recent nationwide laboratory launches of Alzheimer's blood tests illustrate their pivotal role. Reference laboratories are a large and fast-growing end user, performing complex, specialized, and high-sensitivity assays such as liquid biopsy and ultra-sensitive neurological testing, while academic and research institutes drive biomarker discovery and validation, and pharmaceutical and biotechnology companies use blood-based biomarkers for clinical trials and companion diagnostics. Nonetheless, the volume, infrastructure, and clinical centrality of hospital and diagnostic laboratories secure their leadership across the forecast period.

Blood Based Biomarkers Market Region Analysis

Dominant Region: North America

North America accounted for 44% of the global Blood Based Biomarkers market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects advanced healthcare infrastructure, high healthcare spending, and strong adoption of advanced diagnostics, a high burden of cancer and neurological disease, and the concentration of leading diagnostics companies, particularly in the United States. North America leads in regulatory clearances and clinical adoption, exemplified by the 2025 FDA clearance of the first blood test to aid Alzheimer's diagnosis and its rapid nationwide laboratory launch, the clearance of plasma tau tests for primary care, and earlier clearances of point-of-care brain-injury biomarker tests. The region hosts a deep pool of diagnostics leaders and liquid-biopsy innovators, robust oncology and neurology pipelines, significant research funding, and growing payer engagement, supported by professional-society guidelines endorsing blood-based testing. Strong infrastructure, regulatory leadership, and innovation anchor the region's continued leadership across the forecast period.

Dominant: North America ~ 44% (Largest)

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Blood Based Biomarkers market. The region's elevated CAGR is driven by a large and aging population, a rising burden of cancer, cardiovascular, and neurological disease, expanding healthcare access and investment, and growing adoption of advanced diagnostics across China, Japan, India, South Korea, and Australia. Increasing awareness of liquid biopsy and non-invasive testing, expanding laboratory infrastructure, government initiatives to improve early diagnosis, and strong regional diagnostics and research activity are accelerating adoption. Japan in particular is advancing neurodegenerative-disease diagnostics, and regional players are scaling cost-effective testing. Rising chronic-disease prevalence, growing healthcare expenditure, and expanding access position Asia-Pacific as the principal source of incremental growth over the forecast period.

Regional Commentary

North America

North America accounted for 44% of the global Blood Based Biomarkers market revenue in 2025. The United States dominates on the strength of advanced infrastructure, high healthcare spending, regulatory leadership including the first FDA-cleared Alzheimer's blood test, a dense base of diagnostics and liquid-biopsy companies, and strong research funding, while Canada contributes through oncology liquid-biopsy and neurology adoption.

Europe

Europe is a large and advanced regional market, led by Germany, the United Kingdom, France, Italy, and Spain. Growth is supported by strong public health systems, rising awareness of liquid biopsy and blood-based testing, active neurodegenerative-disease research, and a robust base of diagnostics companies, while the in vitro diagnostic regulation shapes the evidence requirements and adoption of new tests across the region.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by a large aging population, rising cancer, cardiovascular, and neurological disease burden, expanding healthcare access and investment, and growing adoption of advanced diagnostics across China, Japan, India, South Korea, and Australia. Regional diagnostics players scale cost-effective testing, while government early-diagnosis initiatives and neurodegenerative-disease research broaden access.

Rest of World

The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging contributor. A rising burden of cancer and chronic disease, expanding healthcare access, and growing interest in non-invasive diagnostics are creating early demand, while partnerships, laboratory capacity building, and improving reimbursement gradually extend access to blood-based biomarker testing across these markets over the forecast period.

Blood Based Biomarkers Market Competitive Landscape

The Blood Based Biomarkers market is classified as Moderately Concentrated. A group of large diagnostics leaders, including Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific, holds substantial share through broad immunoassay and molecular platforms, extensive clinical evidence, and global distribution, while a dynamic field of laboratory networks and specialized innovators, including Quest Diagnostics, Labcorp, Quanterix, Fujirebio, Guardant Health, and other liquid-biopsy and neurodegenerative-biomarker players, intensifies competition through novel biomarkers and advanced detection technologies.

The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with large diagnostics leaders alongside a dynamic field of laboratory networks and specialized liquid-biopsy and neuro innovators.
• Leading players: Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific anchor the top tier through broad platforms and clinical evidence.
• Geographic reach: Leaders operate global commercial and laboratory networks, with strong positions across North America, Europe, and Asia-Pacific.
• Product portfolio strength: Top players hold integrated immunoassay, molecular, and sequencing portfolios spanning oncology, cardiology, and neurology.
• Pipeline and evidence strength: Regulatory clearances and large clinical datasets, such as the first FDA-cleared Alzheimer's blood tests, are decisive competitive assets.
• Strategic partnerships: Collaborations between diagnostics and pharmaceutical companies, such as Biogen with Beckman Coulter and Fujirebio, accelerate test development.
• M&A activity: Active consolidation as players acquire biomarker technologies and liquid-biopsy and neurodegenerative capabilities to broaden portfolios.
• Technology platforms: Ultra-sensitive immunoassays, next-generation sequencing, digital polymerase chain reaction, and mass spectrometry differentiate providers.
• Innovation focus: Liquid biopsy and circulating tumor DNA, plasma tau neurological markers, multi-biomarker panels, and AI-driven interpretation.

Blood Based Biomarkers Market Recent Developmental Activities

In May 2025, Fujirebio Holdings, Inc., received FDA 510(k) clearance for its Lumipulse G pTau217/Beta-Amyloid 1-42 Plasma Ratio test, the first FDA-cleared blood-based in vitro diagnostic in the United States to aid identification of amyloid pathology associated with Alzheimer's disease. Strategic significance: Opened the era of FDA-cleared Alzheimer's blood testing and accelerated clinical adoption.

In August 2025, Laboratory Corporation of America Holdings, launched the FDA-cleared Alzheimer's plasma biomarker blood test nationwide, broadening patient access across the United States. Strategic significance: Demonstrated rapid laboratory-network scale-up of Alzheimer's blood testing and expanded clinical reach.

Blood Based Biomarkers Market Segmentation

Blood Based Biomarkers Market by Type

• Genetic Biomarkers
• Protein Biomarkers
• Cellular Biomarkers
• Metabolite Biomarkers

Blood Based Biomarkers Market by Application

• Oncology
• Cardiovascular Diseases
• Neurological Diseases
• Metabolic and Other Diseases

Blood Based Biomarkers Market by Technology

• Immunoassays
• Polymerase Chain Reaction
• Next-Generation Sequencing
• Mass Spectrometry
• Others

Blood Based Biomarkers Market by Sample Type

• Whole Blood
• Plasma
• Serum

Blood Based Biomarkers Market by End User

• Hospital and Diagnostic Laboratories
• Reference Laboratories
• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies

Blood Based Biomarkers Market by Geography

• North America Blood Based Biomarkers Market
• United States Blood Based Biomarkers Market Size in USD million (2023-2034)
• Canada Blood Based Biomarkers Market Size in USD million (2023-2034)
• Mexico Blood Based Biomarkers Market Size in USD million (2023-2034)
• Europe Blood Based Biomarkers Market
• Germany Blood Based Biomarkers Market Size in USD million (2023-2034)
• United Kingdom Blood Based Biomarkers Market Size in USD million (2023-2034)
• France Blood Based Biomarkers Market Size in USD million (2023-2034)
• Italy Blood Based Biomarkers Market Size in USD million (2023-2034)
• Spain Blood Based Biomarkers Market Size in USD million (2023-2034)
• Rest of Europe Blood Based Biomarkers Market Size in USD million (2023-2034)
• Asia-Pacific Blood Based Biomarkers Market
• China Blood Based Biomarkers Market Size in USD million (2023-2034)
• Japan Blood Based Biomarkers Market Size in USD million (2023-2034)
• India Blood Based Biomarkers Market Size in USD million (2023-2034)
• South Korea Blood Based Biomarkers Market Size in USD million (2023-2034)
• Australia Blood Based Biomarkers Market Size in USD million (2023-2034)
• Rest of Asia-Pacific Blood Based Biomarkers Market Size in USD million (2023-2034)
• Rest of the World (RoW) Blood Based Biomarkers Market
• Middle East Blood Based Biomarkers Market Size in USD million (2023-2034)
• Africa Blood Based Biomarkers Market Size in USD million (2023-2034)
• South America Blood Based Biomarkers Market Size in USD million (2023-2034)

Key Takeaways from the Blood Based Biomarkers Market Report Study

• Market size analysis for the current blood based biomarkers market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global blood based biomarkers market.
• Various opportunities available for competitors in the blood based biomarkers market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current blood based biomarkers market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for blood based biomarkers market growth in the future?

Target audience who can benefit from this blood based biomarkers market report study

• Blood Based Biomarkers product providers
• Research organizations and consulting companies
• Blood Based Biomarkers-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in blood based biomarkers
• Various end-users who want to know more about the blood based biomarkers market and the latest technological developments in the blood based biomarkers market.

Frequently Asked Questions:

Q1. What is the growth rate of the Blood Based Biomarkers market?

The Blood Based Biomarkers market is projected to expand at a CAGR of 9.0% during the forecast period from 2026-2034.

Q2. What is the market size of the Blood Based Biomarkers market?

The Blood Based Biomarkers market is estimated at USD 8.50 billion in 2025 and is projected to reach USD 18.50 billion by 2034.

Q3. Which region dominates the Blood Based Biomarkers market?

North America dominated the Blood Based Biomarkers market with a 44% share of global revenue in 2025, supported by advanced infrastructure, high healthcare spending, regulatory leadership including the first FDA-cleared Alzheimer's blood test, and a dense base of diagnostics and liquid-biopsy companies. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Blood Based Biomarkers market?

The principal drivers are the rising global cancer burden, with the International Agency for Research on Cancer projecting cancer cases to rise from 20 million in 2022 to 35 million by 2050; the growing burden of neurological disease and the Alzheimer's blood-test wave; accelerating FDA clearances and professional-guideline support; the maturation of liquid biopsy; and the broad shift toward non-invasive, preventive testing supported by AI and multi-biomarker panels.

Q5. Who are the major players in the Blood Based Biomarkers market?

The major players include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Bio-Rad Laboratories, Inc., Quanterix Corporation, Fujirebio Holdings, Inc., and Guardant Health, Inc., among other active providers profiled in the Competitive Landscape section. Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific lead through broad platforms and clinical evidence.